Form 4: Alto Neuroscience Director Radhakrishnan Maha Acquires Stock Options

Director Radhakrishnan Maha acquired stock options in Alto Neuroscience, Inc. on March 8, 2024, as part of their compensation.

Summary

• On March 8, 2024, Radhakrishnan Maha, a director of Alto Neuroscience, Inc., acquired stock options to purchase shares of common stock.
• The first stock option grants the right to buy 30,574 shares at an exercise price of $13.76 per share, vesting in 36 equal monthly installments starting April 8, 2024.
• The second stock option grants the right to buy 1,590 shares at an exercise price of $13.76 per share, with 123 shares vesting on March 31, 2024, and 489 shares vesting quarterly thereafter.
• This second option was issued in lieu of $16,263.74 in retainer fees under the company's Non-Employee Director Compensation Policy.
• Both options expire on March 7, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction related to director compensation, which is generally viewed neutrally. The use of stock options can be seen as a positive sign, aligning director interests with shareholders, but it's not a major catalyst for significant positive sentiment.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.
• Using stock options in lieu of cash retainer fees conserves the company's cash resources.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry. This aligns management's interests with shareholders and incentivizes long-term value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice among publicly traded companies, especially in the biotech sector.
• The vesting schedule of the options is typical, designed to incentivize continued service.
• The exercise price is set at $13.76, which may be compared to the market price of ANRO shares at the time of the grant to assess the potential value to the director.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders: Aligns director's interests with shareholder value.
• Employees: No direct impact.
• Company: Conserves cash by using stock options instead of cash compensation.

Key Dates